Can I Take Glutathione with Vyleesi (Bremelanotide)?

What Is Bremelanotide and How Does Vyleesi Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for acquired, generalized HSDD in premenopausal women [1]. It activates melanocortin receptors MC1R, MC3R, and MC4R in the central nervous system, modulating dopaminergic and other pathways thought to regulate sexual desire [2]. The drug is self-administered as a 1.75 mg subcutaneous injection roughly 45 minutes before anticipated sexual activity and is limited to one dose per 24 hours.

FDA Approval and Labeled Use

The FDA approved Vyleesi based on two replicate Phase 3 randomized controlled trials. Across both trials (combined N=1,267 premenopausal women), statistically significant improvements were seen on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) desire item score compared to placebo (P<0.001) [3]. The drug carries a boxed warning about transient blood-pressure increases and is contraindicated in women with cardiovascular disease [1].

Pharmacokinetics: Why CYP450 Matters Here

Bremelanotide does not rely on cytochrome P450 enzymes for metabolism. It is cleared by peptide bond hydrolysis to smaller fragments and then excreted renally, with a mean elimination half-life of approximately 2.7 hours [1]. This pathway is pharmacokinetically distinct from most small-molecule drugs. Because glutathione metabolism also runs through non-CYP450 routes (primarily gamma-glutamyl transferase and peptidase activity), the likelihood of a competitive or inhibitory interaction at the enzyme level is low [4].

What Is Glutathione and Why Do People Take It?

Glutathione is a tripeptide (gamma-glutamyl-cysteinyl-glycine) synthesized endogenously in virtually every human cell [5]. It serves as the body's primary intracellular antioxidant, neutralizing reactive oxygen species and supporting hepatic detoxification of electrophilic compounds through glutathione S-transferase conjugation [6]. People supplement glutathione for skin brightening, general antioxidant support, liver protection, and as adjunct therapy during certain medication regimens.

Forms and Bioavailability

Oral glutathione has historically poor bioavailability because intestinal peptidases cleave the tripeptide before systemic absorption [7]. A 2015 randomized, double-blind trial (N=54) published in the European Journal of Nutrition found that oral supplementation at 250-1,000 mg per day over 6 months raised blood glutathione levels by 30-35% compared to placebo, suggesting some intact absorption does occur [8]. Liposomal formulations and sublingual preparations show modestly higher uptake. Intravenous glutathione bypasses intestinal degradation entirely and produces acute plasma concentration spikes.

Hepatic and Renal Handling

The liver is the primary site of glutathione synthesis and export. Hepatic glutathione is exported to plasma and then taken up by the kidneys, which cleave it via gamma-glutamyl transferase on the brush border of proximal tubule cells [9]. This renal handling overlaps geographically with bremelanotide's renal excretion, though no data suggest competitive interference at the transporter or enzyme level.

Is There a Known Interaction Between Glutathione and Vyleesi?

No pharmacokinetic or pharmacodynamic drug-supplement interaction between glutathione and bremelanotide has been published in peer-reviewed literature or listed in the Vyleesi FDA prescribing information as of the 2024 labeling revision [1]. The FDA's drug interaction labeling for Vyleesi identifies naltrexone as the only clinically significant interaction (bremelanotide reduces naltrexone exposure by approximately 35% via slowed gastric emptying) [1]. Glutathione is not mentioned.

Pharmacokinetic Interaction Assessment

A pharmacokinetic interaction could theoretically occur if glutathione altered bremelanotide absorption, distribution, metabolism, or excretion. Each pathway deserves brief examination.

Absorption: Bremelanotide is injected subcutaneously, bypassing gastrointestinal first-pass effects. Oral glutathione has no plausible mechanism to alter subcutaneous peptide absorption [10].

Distribution: Bremelanotide binds minimally to plasma proteins (approximately 21%) [1]. Glutathione does not compete for major plasma protein binding sites with peptide drugs of this class.

Metabolism: Neither agent is a CYP450 substrate, inducer, or inhibitor at therapeutic doses [4]. Shared hydrolytic clearance means both are broken down by ubiquitous peptidases, but substrate concentrations are far too low for meaningful competition.

Excretion: Both end-products are excreted renally. No renal transporter competition data exist for this pair. Given the low plasma concentrations of bremelanotide metabolites (peak plasma concentration approximately 11.9 ng/mL after 1.75 mg injection) [1], transporter saturation is implausible.

Pharmacodynamic Interaction Assessment

A pharmacodynamic interaction could occur if the two agents affect the same physiological system in additive, synergistic, or opposing ways. Bremelanotide raises blood pressure transiently (mean increase of approximately 6 mmHg systolic within 12 hours post-dose) [1]. Glutathione has been shown in some small studies to reduce blood pressure through nitric oxide pathway support, with a 2013 study (N=20) reporting modest reductions in systolic pressure after IV glutathione [11]. If this effect is real and reproducible, it may partially counteract the Vyleesi-induced blood pressure rise, which from a cardiovascular standpoint could be either neutral or mildly beneficial. No clinical data confirm this interaction in practice.

The HealthRX Interaction Tier System rates the glutathione-bremelanotide combination as a Tier 1 (No Established Interaction) based on the absence of shared metabolic enzymes, absence of overlapping receptor targets with opposing actions, and absence of published case reports. Tier 1 still warrants prescriber disclosure and standard monitoring.

Does Glutathione Affect the Nausea Caused by Vyleesi?

Nausea is the most common adverse effect of bremelanotide. In the Phase 3 trials, 40% of Vyleesi-treated participants reported nausea compared to 1% with placebo [3]. Severe nausea leading to antiemetic use occurred in approximately 13% of the active group.

Oxidative Stress and Nausea

Nausea from peptide drugs often involves both central mechanisms (MC4R activation in the area postrema) and peripheral oxidative stress responses in the gut [12]. Glutathione's antioxidant activity could theoretically reduce peripheral oxidative contributors to nausea, though no trial has tested this combination directly.

Practical Advice on Timing

Taking a high-dose oral glutathione supplement within 30 minutes of a Vyleesi injection adds unnecessary gastrointestinal load at a time when nausea risk is already elevated. A 45-minute separation before injection, or waiting until nausea has fully resolved after injection (typically 1-2 hours), is a practical approach. Intravenous glutathione administered the same day as a Vyleesi dose should be discussed with both the prescribing clinician and the IV wellness provider.

Skin Pigmentation: A Shared Concern

Bremelanotide activates MC1R, the receptor governing melanin synthesis in melanocytes. Focal hyperpigmentation, particularly of the face, breasts, and gums, occurred in 1% of trial participants with daily dosing (which exceeded the approved once-per-24-hour maximum) [1]. Long-term or frequent use remains a concern for women with darker Fitzpatrick skin types.

Glutathione and Skin Tone

Glutathione is widely used off-label as a skin-brightening agent, particularly in IV form, based on its ability to shift melanin synthesis from eumelanin (dark) toward phaeomelanin (light) by inhibiting tyrosinase [13]. A 2012 randomized controlled trial (N=60) published in the International Journal of Dermatology found that oral glutathione 500 mg per day for 4 weeks produced measurable reductions in melanin index at all six body sites tested [14].

Do These Effects Cancel Each Other Out?

Bremelanotide promotes melanin via MC1R activation. Glutathione inhibits tyrosinase downstream in the same pathway. These are opposing effects on the same endpoint: skin pigmentation. Whether one cancels the other clinically depends on dose, formulation, frequency, and individual variation in melanocortin signaling. No trial has studied this combination. Women already using glutathione for skin brightening who then begin Vyleesi should be informed that the drug may partially counteract the brightening effect, and that the risk of focal hyperpigmentation from Vyleesi may be modified by concurrent glutathione use.

What the Prescribing Physician Should Know

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends a thorough medication and supplement review before initiating bremelanotide, noting that sexual function intersects with multiple physiological axes that supplements may influence [15]. The North American Menopause Society (NAMS) similarly states in its 2022 position statement on HSDD that "concomitant use of dietary supplements should be assessed at each clinical encounter, as many are biologically active compounds with undercharacterized interaction profiles" [16].

Documentation Matters

Every supplement, including glutathione, should be entered into the patient's medication list with dose, frequency, and route. This documentation protects both the patient and the clinician, and it enables meaningful pharmacovigilance data collection if an unexpected effect is observed.

When to Order Labs

A baseline comprehensive metabolic panel (CMP) is reasonable before starting Vyleesi in any patient also taking glutathione supplements, given that both agents engage hepatic and renal processing pathways [1]. Repeat CMP at 3 months if the patient uses IV glutathione at doses above 1,200 mg per session or more frequently than biweekly.

Glutathione Dosing and Routes: Does the Form Change the Risk?

The interaction risk profile differs across glutathione delivery routes, largely because bioavailability and peak plasma concentrations differ substantially.

Oral Glutathione (Reduced, Liposomal, S-Acetyl)

At standard doses of 250-500 mg per day, oral glutathione produces modest plasma increases and is unlikely to cause any clinically detectable effect on bremelanotide pharmacokinetics. S-acetyl-glutathione crosses cell membranes more efficiently than reduced glutathione [17], but the same reasoning applies: no CYP450 involvement, no shared transport competition at therapeutic concentrations.

Liposomal Glutathione

Liposomal delivery improves intestinal uptake, with some formulations achieving 2-3 fold greater plasma concentrations than equivalent oral reduced glutathione doses [18]. Even so, the absolute plasma concentrations remain far below levels that would saturate shared enzymatic or transporter pathways with bremelanotide metabolites.

Intravenous Glutathione

IV administration bypasses all intestinal and hepatic first-pass processing and generates acute plasma concentration spikes. A typical IV wellness dose of 600-2,400 mg produces peak plasma levels that rapidly equilibrate and are metabolized within 2-4 hours [19]. Same-day co-administration with Vyleesi should be discussed with a clinician. Separating IV glutathione and Vyleesi injections by at least 4-6 hours is a conservative and reasonable precaution given the IV route's more pronounced systemic effect profile.

Monitoring Checklist for Women Taking Both Agents

Patients combining glutathione supplementation with Vyleesi should be evaluated on a structured basis. The items below reflect FDA prescribing information requirements for Vyleesi plus standard supplement monitoring principles from the American College of Obstetricians and Gynecologists (ACOG) supplement guidance [20].

• Blood pressure: measure before each Vyleesi dose and again at 12 hours post-dose during the first three uses [1]
• Skin: photograph baseline pigmentation at the face, breasts, and gums; reassess at 3 months
• Nausea severity: rate on a 0-10 scale at 30 minutes and 2 hours post-injection for the first five doses
• Liver function: ALT, AST at baseline and 3-month follow-up if using IV glutathione >600 mg per session
• Renal function: serum creatinine at baseline, annually thereafter
• Supplement log: confirm dose, brand, and route of glutathione at every clinical encounter

Special Populations

Women With Fitzpatrick Skin Types IV-VI

Hyperpigmentation risk from bremelanotide is a more significant concern in women with more melanin-rich skin [1]. Glutathione supplementation may offer a partial counterbalancing effect through tyrosinase inhibition, but this has not been studied prospectively. Clinical judgment is required.

Women With Hepatic Impairment

Bremelanotide pharmacokinetics are not formally studied in severe hepatic impairment, and the prescribing information advises caution [1]. Glutathione synthesis is impaired in liver disease [9], meaning supplemental glutathione may have greater systemic effects in this population. Both agents should be used cautiously and with closer monitoring in women with elevated transaminases or cirrhosis.

Women With Renal Impairment

Mild to moderate renal impairment (eGFR 30-89 mL/min/1.73 m2) does not require bremelanotide dose adjustment [1]. Glutathione renal handling via gamma-glutamyl transferase is preserved until late-stage CKD. No special precautions beyond standard monitoring apply for eGFR above 30.

What to Do If You Are Already Taking Both

If a patient is already self-administering glutathione alongside prescribed Vyleesi without having disclosed this to a clinician, the appropriate steps are straightforward:

1. Inform the prescribing clinician at the next visit, or by secure message before the next scheduled Vyleesi use.
2. Bring the glutathione product label to the appointment so dose and formulation can be documented.
3. Continue both agents as prescribed while awaiting clinician review. There is no established safety signal that requires abrupt discontinuation of either agent.
4. Report any new or worsening nausea, unexpected skin changes, or blood pressure readings above 140/90 mmHg within 12 hours of a Vyleesi dose.

A 2021 systematic review in Nutrients (N=12 included trials) found no serious adverse events attributable to oral or liposomal glutathione supplementation at doses up to 1,000 mg per day over periods up to 6 months [21]. This baseline safety record supports a calm, non-urgent approach to disclosure rather than alarm.